8-K: FOXO Completes Vector Bio Source Acquisition

FOXO Technologies Inc. has finalized its acquisition of Vector Bio Source Inc., expanding its biotechnology and research services.

Summary

• FOXO Technologies Inc. completed the acquisition of Vector Bio Source Inc. on September 19, 2025.
• Vector Bio Source Inc. is an information, data, and biospecimen sourcing provider for the biotechnology, clinical research, and pharmaceutical research industries.
• The acquisition consideration included $500,000 in cash, 60,000 shares of Series E Cumulative Redeemable Secured Preferred Stock (stated value $1.5 million), and warrants to purchase up to $2 million of Class A Common Stock at an exercise price of $0.00517.
• An additional earn-out of up to 80,000 shares of Series E Preferred Stock (stated value $2.0 million) is contingent on Vector achieving specific revenue and cash collection milestones over a future 12 to 24 month period.
• FOXO has committed to funding up to $1.2 million for Vector's growth initiatives.
• Vector reported net revenues of approximately $225,000 for Q2 2025, representing an annual run rate of $0.9 million, with expectations for significant post-acquisition growth.

Sentiment

Score: 7

Explanation: The acquisition is a strategic expansion into a complementary industry with stated growth expectations. While the company has a history of losses, this acquisition could contribute positively to future revenue and diversification. The consideration includes a significant portion of equity, which conserves cash but creates future obligations and potential dilution.

Positives

• The acquisition of Vector Bio Source Inc. expands FOXO's presence in the biotechnology, clinical research, and pharmaceutical research industries.
• Vector generated Q2 2025 net revenues of approximately $225,000, with an annual run rate of $0.9 million, and is expected to grow significantly post-acquisition.
• FOXO's commitment to fund up to $1.2 million for Vector's growth initiatives supports future expansion.
• The acquisition diversifies FOXO's portfolio, adding a data and biospecimen sourcing provider to its existing hospital, behavioral health, and biotech labs operations.

Risks

• General risks associated with forward-looking statements, including the ability to achieve expected growth and financial performance.
• Risks related to operating in competitive and highly regulated industries.
• Variations in operating performance across competitors or changes in laws and regulations affecting FOXO's business.
• Challenges in implementing FOXO's business plans, forecasts, and other expectations.
• The ability to obtain necessary financing for operations and growth initiatives.
• FOXO has a history of losses and may not achieve or maintain profitability in the future.
• Risks concerning the enforceability of FOXO's intellectual property and potential infringement on the intellectual property rights of others.
• Risk of downturns and a changing regulatory landscape in the highly competitive industries in which FOXO operates.

Future Outlook

Vector Bio Source Inc. is expected to grow significantly post-acquisition, supported by FOXO's commitment to fund up to $1.2 million for its growth initiatives. FOXO's management anticipates leveraging internal and external growth opportunities with Vector's senior management.

Management Comments

• "We are pleased to have closed the Vector acquisition and look forward to working with Vector senior management on internal and external growth opportunities." Seamus Lagan, CEO of FOXO.
• "We excited to be part of FOXO and believe the partnership with FOXO will allow Vector to achieve its aggressive growth plans." Frank Dias, Jr., CEO of Vector.

Industry Context

The acquisition of Vector Bio Source Inc. strategically expands FOXO Technologies' footprint into the specialized area of information, data, and biospecimen sourcing for the biotechnology, clinical research, and pharmaceutical research industries. This complements FOXO's existing diverse portfolio, which includes a critical access hospital (Rennova Community Health), a behavioral health facility (Myrtle Recovery Centers), and a biotechnology research arm (FOXO Labs, Inc.). This move suggests FOXO is building an integrated health and biotech ecosystem, potentially creating synergies between its research, data, and healthcare service segments.

Stakeholder Impact

• Shareholders: Potential for future growth and diversification of revenue streams. Issuance of preferred stock and warrants could lead to dilution of common stock holders.
• Employees: Vector employees are now part of FOXO, potentially benefiting from larger corporate resources and growth initiatives.
• Customers: Vector's customers in biotech, clinical research, and pharma may benefit from enhanced services and resources under FOXO's ownership.

Next Steps

• FOXO management will work with Vector senior management on internal and external growth opportunities.
• Vector is expected to achieve certain revenue and cash collection milestones in a future 12 to 24 month period to trigger additional earn-out payments.

Key Dates

Recommendation

The acquisition of Vector Bio Source Inc. is a strategic move that diversifies FOXO's business into a complementary high-growth sector. The expected significant growth of Vector and the funding commitment from FOXO are positive indicators. However, the company's stated history of losses and general risks associated with competitive and regulated industries, as well as the potential dilution from the issuance of preferred stock and warrants, warrant a 'hold' recommendation. Investors should monitor the integration of Vector and its contribution to FOXO's overall profitability and growth before considering a stronger position.

Keywords

FOXO Technologies, Vector Bio Source, Acquisition, Biotechnology, Clinical Research, Pharmaceutical Research, Biospecimen Sourcing, SEC Filing, 8-K, Preferred Stock, Warrants, M&A